Search clinical trials for: Eslicarbazepine acetate (BIA 2-093)

Total 1057 results

Bial - Portela C S.A.

Completed

Eslicarbazepine Acetate (BIA 2 093) as Therapy for Refractory Partial Seizures in Children

Partial Epilepsy in Children and Adolescents

United Kingdom, Spain, Serbia, Italy, Austria, Bosnia and Herzegovina, Croatia, Czechia, France, Germany, Hungary, Malaysia, Moldova, Republic of, Philippines, Poland, Portugal, Romania, Russian Federation, Slovakia, Taiwan, Ukr...
Bial - Portela C S.A.

Terminated

Eslicarbazepine Acetate as Therapy in Diabetic Neuropathic Pain

Painful Diabetic Neuropathy

Portugal
Bial - Portela C S.A.

Completed

Disposition of Eslicarbazepine Acetate and Its Metabolites S-licarbazepine and R-licarbazepine

Epilepsy

Germany
Bial - Portela C S.A.

Terminated

Eslicarbazepine Acetate as Therapy in Post-Herpetic Neuralgia

Post Herpetic Neuralgia

Germany
Bial - Portela C S.A.

Completed

A Sequential Multiple Ascending Dose Study of the Safety and Pharmacokinetics of Eslicarbazepine Acetate in Adult Healthy Volunteers

Epilepsy

United States
Bial - Portela C S.A.

Completed

Pharmacokinetics, Efficacy and Tolerability of BIA 2-093

Epilepsy

Romania
Bial - Portela C S.A.

Completed

An Open-label, Multiple-dose, Single-centre Study, Investigating the Pharmacokinetics of BIA 2-093

Epilepsy

South Africa
Bial - Portela C S.A.

Completed

The Tolerability and Effect of Food on the Pharmacokinetics of a Single 800 mg Oral Dose of BIA 2-093

Epilepsy
Bial - Portela C S.A.

Completed

Single-dose Pharmacokinetics and Relative Bioavailability of an Oral Suspension and Two Tablet Formulations of BIA 2-093

Epilepsy

Portugal
Bial - Portela C S.A.

Completed

Efficacy and Safety Study of BIA 2-093 in Combination With Other Anti-Epileptic Drugs to Treat Partial Epilepsy

Partial Epilepsy

Portugal
Bial - Portela C S.A.

Completed

Effects of Eslicarbazepine Acetate (BIA 2-093) on Cognition and Psychomotor Function

Epilepsy
Bial - Portela C S.A.

Completed

A Double-blind, Randomised, Placebo-controlled, Rising Multiple Dose Study to Investigate the Safety, Tolerability, Steady State Pharmacokinetic Profile and CNS Effects of BIA 2-093

Epilepsy

United Kingdom
Bial - Portela C S.A.

Completed

Effects of Eslicarbazepine Acetate (Esl, Bia 2-093) on Cognitive Function in Children With Partial Onset Seizures

Partial Epilepsy

Netherlands, Poland, Italy, Russian Federation, Ukraine
Bial - Portela C S.A.

Completed

Comparative Bioavailability Study of Two Different Sources of Eslicarbazepine Acetate

Epilepsy
Bial - Portela C S.A.
Sunovion

Completed

Efficacy and Safety of Eslicarbazepine Acetate (BIA 2-093) as Adjunctive Therapy for Refractory Partial Seizures

Partial Epilepsy

United States, Argentina, Germany, France, Belgium, Canada, Italy, Poland, Greece, Brazil, Cyprus
Bial - Portela C S.A.

Completed

Food Effect and Dosage Form Proportionality Study of Eslicarbazepine Acetate

Epilepsy
Bial - Portela C S.A.

Completed

A Study to Evaluate the Tolerability and Pharmacokinetics of Two Single and Multiple High Dose Regimens of BIA 2-093 In Healthy Volunteers

Epilepsy

Portugal
Bial - Portela C S.A.

Completed

The Effect of BIA 2-093 on the Steady-state Pharmacodynamic and Pharmacokinetic Profiles of Warfarin

Epilepsy
Bial - Portela C S.A.

Completed

A Single Centre, Phase I, Double-blind, Randomised, Placebo-controlled Study to Investigate the Safety, Tolerability, Pharmacokinetic Profile and Effects on EEG of Single Rising Oral Doses of BIA 2-093

Epilepsy

United Kingdom
Bial - Portela C S.A.

Completed

Efficacy, Safety, and Tolerability of Eslicarbazepine Acetate in the Recurrence Prevention of Bipolar I Disorder

Bipolar I Disorder
Bial - Portela C S.A.

Completed

Bioequivalence of Two Different Sources of Eslicarbazepine Acetate

Epilepsy
Bial - Portela C S.A.

Completed

Effect of Eslicarbazepine Acetate on the Pharmacokinetics of Gliclazide in Healthy Volunteers

Epilepsy

Portugal
Bial - Portela C S.A.

Completed

Efficacy and Safety of Eslicarbazepine Acetate as Monotherapy for Patients With Newly Diagnosed Partial-onset Seizures

Epilepsy

Portugal
Bial - Portela C S.A.

Completed

A Open-label, Drug Interaction Study Between Eslicarbazepine Acetate and Topiramate

Epilepsy
Bial - Portela C S.A.

Completed

Efficacy and Safety of Eslicarbazepine Acetate as Therapy in Subjects With Fibromyalgia

Fibromyalgia
Bial - Portela C S.A.

Completed

Effect of Repeat Administration of Eslicarbazepine Acetate on the Pharmacokinetics of a Combined Oral Contraceptive

Partial Epilepsy

Portugal
Bial - Portela C S.A.

Completed

An Open-label, Single-dose, Single-centre Study, Investigating the Pharmacokinetics of BIA 2-093

Epilepsy

South Africa
Sunovion

Completed

A Study of a Drug to be Used in Addition With Another Drug to Treat Adults With Uncontrolled Partial-onset Seizures

Epilepsy With Partial On-set Seizures

United States, Canada
Bial - Portela C S.A.

Completed

Single-dose and Steady-state Pharmacokinetics of BIA 2-093 and Its Metabolites

Epilepsy

Germany
Bial - Portela C S.A.

Completed

Single Dose Crossover Comparative Bioavailability Study of Eslicarbazepine Acetate Versus To-be-marketed Formulation

Epilepsy
Sunovion

Completed

Eslicarbazepine Acetate Monotherapy Long Term Study

Epilepsy

United States, Canada, Bulgaria, Ukraine, Czechia, Serbia
Bial - Portela C S.A.

Completed

A Placebo-controlled Study to Investigate Safety and Efficacy of BIA 2-093

Epilepsy

Portugal
Bial - Portela C S.A.

Completed

Steady-state Pharmacokinetics of BIA 2-093 and Oxcarbazepine in Healthy Volunteers

Epilepsy

Portugal
Sunovion

Withdrawn

A Pediatric Drug Study to Determine the Long-term Safety and Tolerability in Children and Adolescents (4-17 Years in Age) Taking the Drug

Epilepsy

United States
Bial - Portela C S.A.

Completed

The Effect of BIA 2-093 on the Steady-state Pharmacokinetics of Digoxin

Epilepsy

Portugal
Bial - Portela C S.A.

Completed

Trial to Evaluate the Effect of Eslicarbazepine Acetate on Cardiac Repolarization

Epilepsy

United States
Bial - Portela C S.A.

Completed

Eslicarbazepine Acetate (BIA 2-093) as Monotherapy in Patients With Newly Diagnosed Partial-onset Seizures

Epilepsy
Bial - Portela C S.A.

Completed

Tolerability and Pharmacokinetics of a Single 900 mg Oral Dose of BIA 2-093 and Oxcarbazepine in Healthy Volunteers

Epilepsy

Portugal
Bial - Portela C S.A.

Completed

Open-label Drug Interaction Study Between Eslicarbazepine Acetate and Phenytoin.

Epilepsy
Bial - Portela C S.A.

Terminated

Efficacy and Safety of Eslicarbazepine Acetate (BIA 2-093) in Acute Manic Episodes Associated With Bipolar I Disorder

BIPOLAR I DISORDER
Bial - Portela C S.A.

Terminated

The Effect of BIA 2-093 on the Steady-state Pharmacokinetic Profile of Phenytoin in Patients

Epilepsy

Portugal
Bial - Portela C S.A.

Completed

Efficacy and Safety of Eslicarbazepine Acetate (BIA 2-093) in Acute Manic Episodes Associated With Bipolar I Disorder

Bipolar I Disorder
Sunovion

Completed

Safety & Efficacy of Eslicarbazepine Monotherapy in Sub.w/Partial Epilepsy Not Well Controlled by Current Antiepileptic

Epilepsy

United States, Bulgaria, Czech Republic, Serbia, Ukraine
Bial - Portela C S.A.

Completed

Effect of BIA 2-093 on the Pharmacokinetics of a Combined Oral Contraceptive.

Epilepsy

Portugal
Bial - Portela C S.A.

Completed

Study to Evaluate Pharmacokinetics and Tolerability of Multiple Doses of Eslicarbazepine Acetate and Oxcarbazepine

Partial Epilepsy

Belgium
Bial - Portela C S.A.

Completed

Safety and Efficacy of Eslicarbazepine Acetate as Adjunctive Therapy for Partial Seizures in Elderly Patients

Epilepsy

Spain, Bulgaria, Austria, Croatia, Czechia, France, Germany, Poland, Portugal, Romania
Centre Hospitalier Saint Joseph Saint Luc de Lyon

Unknown

ZEBinix® Retention Rate in Epilepsy in Elderly Patients (ZEBRE)

Epilepsy | Aging | Epilepsy; Seizure | Aging Disorder

France
Bial - Portela C S.A.

Completed

Efficacy and Safety of Eslicarbazepine Acetate as Adjunctive Therapy for Refractory Partial Seizures

Refractory Partial Epilepsy

Portugal
Eisai Inc.

Completed

A Post-marketing Study Evaluating Eslicarbazepine Acetate (ESL) as Adjunctive Treatment in Partial-Onset Seizures (Study E2093-E044-404) (EPOS)

Partial Onset Seizures

France, United Kingdom, Germany, Denmark, Czech Republic, Norway, Sweden, Ireland
Bial - Portela C S.A.

Completed

Pharmacokinetic Interaction Study Between Eslicarbazepine Acetate and Carbamazepine

Epilepsy

3

Subscribe